tiprankstipranks
Trending News
More News >
Zoetis (ZTS)
NYSE:ZTS
Advertisement

Zoetis (ZTS) AI Stock Analysis

Compare
3,644 Followers

Top Page

ZTS

Zoetis

(NYSE:ZTS)

Rating:76Outperform
Price Target:
$180.00
▲(19.40%Upside)
Zoetis' strong financial performance and positive earnings call guidance are the key drivers of the score, reflecting robust growth and strategic resilience. Technical indicators suggest caution, but the company's commitment to shareholder returns and moderate valuation provide a balanced outlook.
Positive Factors
Financial Performance
Zoetis reported solid first quarter results with organic operational growth at 9%, exceeding expectations.
Market Position
Zoetis stands to benefit from any pet owners pairing Quantum with an injectable heartworm preventative, as Zoetis offers ProHeart injectible.
Product Innovation
Zoetis is increasingly shifting to the combination parasiticide Simparica Trio, which also provides internal parasite protection, making it a more comprehensive solution for pet owners.
Negative Factors
Product Competition
Bravecto Quantum is seen as a potential threat to Zoetis’s Simparica parasiticide franchise.
Product Performance
Librela US sales were slightly worse than expected, continuing a trend of disappointing results over multiple quarters.

Zoetis (ZTS) vs. SPDR S&P 500 ETF (SPY)

Zoetis Business Overview & Revenue Model

Company DescriptionZoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
How the Company Makes MoneyZoetis generates revenue through the sale of its extensive range of animal health products. The company's revenue model primarily revolves around two main segments: companion animal and livestock. The companion animal segment focuses on products for pets, including vaccines, parasiticides, and dermatology products, which are sold directly to veterinarians, clinics, and pet owners. The livestock segment caters to livestock producers, providing vaccines, anti-infectives, and performance-enhancing products aimed at improving animal health and farm productivity. Zoetis also benefits from its strategic partnerships and collaborations with veterinary practices, research institutions, and agricultural businesses, enhancing its market reach and innovation capabilities. Additionally, the company invests significantly in research and development to sustain its pipeline of new products, ensuring a steady stream of innovative solutions to meet evolving market demands.

Zoetis Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas are driving growth and profitability, and indicating strategic focus and diversification.
Chart InsightsZoetis' Companion Animal segment shows strong growth momentum, with a notable surge in recent quarters, driven by the Simparica franchise and dermatology products. This aligns with the earnings call highlighting a 19% growth in Simparica and a 9% overall increase in the segment. Meanwhile, the Livestock segment faces challenges, particularly in the US, with a decline due to price competition and supply timing issues. Despite these challenges, the company maintains a positive outlook, expecting 6-8% organic revenue growth, supported by innovation and strategic investments.
Data provided by:Main Street Data

Zoetis Earnings Call Summary

Earnings Call Date:May 06, 2025
(Q1-2025)
|
% Change Since: -4.30%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook for Zoetis, with strong growth in key segments and strategic resilience against macroeconomic challenges. While there are concerns around the slower adoption of Librela and tariff impacts, the overall market position remains robust with continued innovation and demand for their diverse portfolio.
Q1-2025 Updates
Positive Updates
Strong Organic Operational Revenue Growth
Zoetis achieved a 9% organic operational revenue growth in Q1 2025, driven by a balanced portfolio. The International segment led with 11% growth, while the US grew 6% excluding the impact of the MFA divestiture.
Innovative Companion Animal Portfolio Performance
The companion animal portfolio grew 9% operationally, driven by strong demand for the Simparica franchise, which posted a 19% growth, and key dermatology products which grew by 10%.
Livestock Segment Growth
The livestock segment experienced a 7% organic operational growth, driven by broad-based double-digit performance internationally.
Strong Adjusted Net Income and EPS Growth
Adjusted net income grew 6% on an organic operational basis, and adjusted diluted EPS grew 8% on the same basis, driven by robust share repurchase activities.
Resilient Market Position Amid Economic Challenges
Zoetis maintains steady demand for its products and is well-positioned to navigate tariff impacts with a 60% US manufacturing footprint and strategic global reach.
Negative Updates
Librela Adoption Slower Than Expected
Adoption of Librela has been more gradual than initially anticipated, with a noted shift in consumer spending reflecting broader economic trends.
US Livestock Decline
The US livestock segment experienced a 2% organic operational decline, impacted by aggressive price competition and timing of supply and price adjustments.
Tariff Impact Concerns
Current enacted tariffs have resulted in a $20 million headwind, primarily affecting imports related to APIs and certain diagnostic products.
Company Guidance
In the first quarter of 2025, Zoetis reported a robust 9% organic operational revenue growth, driven by a 6% increase in adjusted net income on an organic operational basis. The International segment showed impressive performance with an 11% organic operational revenue growth, while the US segment grew by 6%, excluding the impact of the MFA divestiture. The companion animal portfolio, notably the Simparica franchise, experienced a 19% growth, contributing $367 million in revenue, while the overall companion animal portfolio grew by 9% operationally. Livestock also saw a 7% organic operational growth. Zoetis maintained a full-year organic operational revenue guidance range of 6% to 8%, despite macroeconomic uncertainties. Adjusted net income for the full year is expected to grow between 5% and 7% on an organic operational basis, with adjusted diluted EPS projected to be between $6.20 and $6.30. The company continues to focus on innovation, customer engagement, and strategic investments to manage challenges and leverage opportunities in the evolving market landscape.

Zoetis Financial Statement Overview

Summary
Zoetis demonstrates strong revenue growth and profitability with a stable balance sheet, although there is room for improvement in cash flow utilization and equity strength.
Income Statement
85
Very Positive
Zoetis has demonstrated strong revenue growth with a consistent upward trajectory over the years. The gross profit margin is robust, indicating efficient cost management. The net profit margin and EBIT margin are healthy, showcasing profitability and operational efficiency. However, the EBITDA margin shows room for improvement compared to peers.
Balance Sheet
78
Positive
The company's balance sheet reflects a stable financial position with a moderate debt-to-equity ratio, indicating manageable leverage. The return on equity is strong, suggesting effective use of shareholder funds. However, the equity ratio is relatively low, which could pose risks if liabilities increase.
Cash Flow
82
Very Positive
Zoetis exhibits strong cash flow generation with consistent free cash flow growth, supporting operational and strategic initiatives. The operating cash flow to net income ratio is robust, indicating efficient cash conversion. However, the free cash flow to net income ratio suggests potential for further improvement in cash utilization.
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Zoetis Technical Analysis

Technical Analysis Sentiment
Negative
Last Price150.75
Price Trends
50DMA
159.38
Negative
100DMA
158.19
Negative
200DMA
165.02
Negative
Market Momentum
MACD
-2.24
Negative
RSI
40.41
Neutral
STOCH
54.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZTS, the sentiment is Negative. The current price of 150.75 is below the 20-day moving average (MA) of 153.99, below the 50-day MA of 159.38, and below the 200-day MA of 165.02, indicating a bearish trend. The MACD of -2.24 indicates Negative momentum. The RSI at 40.41 is Neutral, neither overbought nor oversold. The STOCH value of 54.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZTS.

Zoetis Risk Analysis

Zoetis disclosed 47 risk factors in its most recent earnings report. Zoetis reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Zoetis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$67.12B27.0751.85%1.28%6.32%7.23%
71
Outperform
$7.24B19.466.01%1.42%
71
Outperform
$12.37B18.3818.36%0.03%13.03%-0.49%
67
Neutral
$1.17B37.0111.86%1.66%19.12%141.45%
65
Neutral
$3.16B83.205.06%-25.48%-63.36%
54
Neutral
$10.87B-21.25%5.18%-6.88%-6809.78%
52
Neutral
$7.59B0.18-63.14%2.16%16.34%0.64%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ZTS
Zoetis
150.75
-28.89
-16.08%
RDY
Dr Reddy's Laboratories
14.70
-1.34
-8.35%
VTRS
Viatris
9.26
-2.32
-20.03%
PAHC
Phibro Animal Health
28.92
10.93
60.76%
HCM
HUTCHMED
17.98
-0.02
-0.11%
ELAN
Elanco Animal Health
14.58
1.68
13.02%

Zoetis Corporate Events

Executive/Board ChangesShareholder Meetings
Zoetis Elects New Board Member at Annual Meeting
Neutral
May 22, 2025

On May 21, 2025, Zoetis Inc. held its Annual Meeting of Shareholders, where Dr. Mark Stetter was elected to the Board of Directors, succeeding Mr. Robert Scully who retired in accordance with the company’s director retirement policy. Dr. Stetter, with extensive experience in veterinary medicine and animal health, is expected to contribute significantly to Zoetis’ mission of advancing animal care. The meeting also saw the election of twelve directors, approval of the executive compensation program, and ratification of KPMG LLP as the independent registered public accounting firm, though a shareholder proposal for special meeting improvements was not approved.

The most recent analyst rating on (ZTS) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.

Dividends
Zoetis Announces Q3 2025 Dividend of $0.50
Positive
May 21, 2025

On May 21, 2025, Zoetis announced a dividend of $0.50 per share for the third quarter of 2025, payable on September 3, 2025, to shareholders recorded by July 18, 2025. This decision reflects the company’s ongoing commitment to returning value to its shareholders and may impact its financial positioning and stakeholder relations.

The most recent analyst rating on (ZTS) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025